Target
TP53 R175H
1 abstract
Abstract
Open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-175 in human leukocyte antigen-a*02:01-positive adult subjects with unresectable, advanced and/or metastatic solid tumors that are positive for the TP53 R175H mutation.Org: Baylor Charles A. Sammons Cancer Center, Neogene Therapeutics, Inc. – An AstraZeneca Group company,